Program Director/Principal Investigator (Last, First, Middle):
BIOGRAPHICAL SKETCH
Provide the following information for the Senior/key personnel and other significant contributors in the order listed on Form Page 2.
Follow this format for each person. DO NOT EXCEED FOUR PAGES.
NAME
POSITION TITLE
Zhou, Dong
Research Instructor in Radiology
eRA COMMONS USER NAME (credential, e.g., agency login)
EDUCATION/TRAINING (Begin with baccalaureate or other initial professional education, such as nursing, include postdoctoral training and
residency training if applicable.)
DEGREE
INSTITUTION AND LOCATION
MM/YY
FIELD OF STUDY
(if applicable)
Shandong University
Jinan, Shandong, China
B.S.
1990
Chemistry
Shandong University
Shandong, China
M.S.
1995
Polymer Chemistry and
Physics
Washington University
St. Louis, Missouri
Ph.D.
2004
Organic Chemistry
Washington University, School of Medicine
St. Louis, Missouri
Postdoctoral
Research
Associate
2004-2007
Radiochemistry and
Radiopharmaceuticals
A. Personal Statement
My research focuses on fluorine-18 radiochemistry and development of novel PET tracers for preclinical and
clinical applications, including new method development of fluorine-18 labeling, novel PET tracer development
for imaging of targets with clinical relevance, and translation and optimization of labeling methods for
automated production.
B. Positions and Honors
Positions and Employment
1995-1998
Lecturer, Department of Chemistry, Jinan University, Jinan, Shandong, China
2007-present Research Instructor, Mallinckrodt Institute of Radiology, School of Medicine, Washington
University in St. Louis, Missouri
Honors
2009
“Synthesis, radiolabeling, and in vivo evaluation of an 18F-labeled isatin analog for imaging
caspase-3 activation in apoptosis” was awarded “The Most Cited Paper 2006-2009 Award” in
Bioorganic & Medicinal chemistry Letters.
C. Selected Peer-reviewed Publications
Most relevant to the current application
1. D. Zhou, W. Chu, J. Rothfuss, C. Zeng, J. Xu, L. Jones, M. J. Welch, R. H. Mach, “Synthesis,
radiolabeling, and in vivo evaluation of an 18F-labeled isatin analog for imaging caspase-3 activation in
apoptosis.” Bioorgan. Med. Chem. Lett. 16(19), 5041 (2006).
2. D. Zhou, W. Chu, Q. Wang, D. E. Reichert, J. Rothfuss, A. D'Avignon, M. J. Welch, R. H. Mach, “Design,
Synthesis, Radiolabeling Mechanism, and Modeling Study of [18F] and [11C] N-Benzyl-isatin Sulfonamide
Analogs for Imaging Caspase-3/7 Activation in Apoptosis.” Org. Biomol. Chem. 7(7), 1337 (2009).
3. D. Zhou, H. Lee, J. M. Rothfuss, D. L. Chen, D. E. Ponde, M. J. Welch, R. H. Mach, “Design and
PHS 398/2590 (Rev. 06/09)
Page
Biographical Sketch Format Page
Program Director/Principal Investigator (Last, First, Middle):
4.
5.
6.
7.
8.
9.
10.
11.
12.
13.
14.
15.
16.
17.
18.
Synthesis of 2-Amino-4-methylpyridine Analogues as Inhibitors for Inducible Nitric Oxide Synthase and in
vivo Evaluation of [18F]6-(2-Fluoropropyl)-4-methyl-pyridin-2-amine as a Potential PET Tracer for Inducible
Nitric Oxide Synthase.” J. Med. Chem. 52(8), 2443 (2009).
D. L. Chen, D. Zhou, W. Chu, P. E. Herrbrich, L. A. Jones, J. M Rothfuss, J. T. Engle, M. Geraci, M. J.
Welch, R. Mach, “Comparison of radiolabeled isatin analogs for imaging apoptosis with positron emission
tomography.” Nucl. Med. Biol. 36(6), 651 (2009).
J. McConathy, D. Zhou, S. E. Shockley, L. A. Jones, E. A. Griffin, H. Lee, S. J. Adams, R. H. Mach, “Click
Synthesis and Biological Evaluation of (R)- and (S)-2-amino-3-[1-(2-[18F]fluoroethyl)- 1H-[1,2,3]triazol-4yl]propanoic acid for Brain Tumor Imaging with PET.” Mol. Imaging, 9(6), 329 (2010).
D. L. Chen, D. Zhou, W. Chu, P. Herrbrich, J. T. Engle, E. Griffin, L. A. Jones, J. M. Rothfuss, M. Geraci,
R. S. Hotchkiss, R. H. Mach. “Radiolabeled isatin binding to caspase-3 activation induced by anti-Fas
antibody.” Nucl. Med. Biol. 39(1), 137, (2012).
A. M. Fowler, S. R. Chan, T. L. Sharp, N. M. Fettig, D. Zhou, C. S. Dence, K. E. Carlson, M. Jeyakumar, J.
A. Katzenellenbogen, R. D. Schreiber, M. J. Welch. “Small-animal PET of steroid hormone receptors
predicts tumor response to endocrine therapy using a preclinical model of breast cancer.” J. Nucl. Med.
53(7), 1119 (2012).
D. Zhou, M. Lin, N. Yasui, M. H. Al-Qahtani, C. S. Dence, S. Schwarz, J. A. Katzenellenbogen.
“Optimization of the preparation of fluorine-18-labeled steroid receptor ligands 16alpha-[18F]fluoroestradiol
(FES), [18F]fluoro furanyl norprogesterone (FFNP), and 16beta-[18F]fluoro-5alpha-dihydrotestosterone
(FDHT) as radiopharmaceuticals.” J. Labelled Comp. Radiopharm. 57(5), 371 (2014).
D. Zhou, W. Chu, J. Xu, L. A. Jones,X. Peng, S. Li, D. L. Chen, R. H. Mach. “Synthesis, [18F] radiolabeling,
and evaluation of poly (ADP-ribose) polymerase-1 (PARP-1) inhibitors for in vivo imaging of PARP-1 using
positron emission tomography” Bioorg. Med. Chem. 22(5), 1700 (2014).
W. Chu, A. Chepetan, D. Zhou, K. I. Shoghi, J. Xu, L. L. Dugan, R. J. Gropler, M. A. Mintun, R. H. Mach.
“Development of a PET radiotracer for non-invasive imaging of the reactive oxygen species, superoxide, in
vivo.” Org. Biomol. Chem. 12(25), 4421 (2014).
Additional recent publications of importance to the field
W. Chu, J. Rothfuss, A. d'Avignon, C. Zeng, D. Zhou, R. S. Hotchkiss, R. H. Mach, “Isatin Sulfonamide
Analogs Containing a Michael Addition Acceptor: A New Class of Caspase 3/7 Inhibitors” J. Med. Chem.
50(15), 3751 (2007).
W. Chu, J. Xu, D. Zhou, F, Zhang, L. A. Jones, K. T. Wheeler, R. H. Mach, New “N-substituted 9azabicyclo[3.3.1]nonan-3alpha-yl phenylcarbamate analogs as sigma(2) receptor ligands: Synthesis, in
vitro characterization, and evaluation as PET imaging and chemosensitization agents.” Bioorg. Med.
Chem. 17(3), 1222 (2009).
W. Chu, J. Rothfuss, Y. Chu, D. Zhou, R. H. Mach, “Synthesis and in vitro evaluation of sulfonamide isatin
Michael acceptors as small molecule inhibitors of caspase-6.” J. Med. Chem. 52(8), 2188 (2009).
J. Xu, C. Zeng, W. Chu, F. Pan, J. M. Rothfuss, F. Zhang, Z. Tu, D. Zhou, D. Zeng, S. Vangveravong, F.
Johnston, D. Spitzer, K. C. Chang, R. S. Hotchkiss, W. G. Hawkins, K. T. Wheeler, R. H. Mach.
“Identification of the PGRMC1 protein complex as the putative sigma-2 receptor binding site.” Nat.
Commun. 2, 380 (2011).
W. Chu, J. Rothfuss, D. Zhou, R. H. Mach, “Synthesis and evaluation of isatin analogs as caspase-3
inhibitors: introduction of a hydrophilic group increases potency in a whole cell assay.” Bioorg. Med. Chem.
Lett. 21(8), 2192 (2011).
F. Dehdashti, R. Laforest, F. Gao, R. L. Aft, C. S. Dence, D. Zhou, K. I. Shoghi, B. A. Siegel, J. A.
Katzenellenbogen, M. J. Welch. “Assessment of Progesterone Receptors in Breast Carcinoma by PET
with 21-18F-Fluoro-16α,17α-[(R)-(1'-α-furylmethylidene)Dioxy]-19-Norpregn-4-Ene-3,20-Dione.” J Nucl
Med. 53(3), 363 (2012).
D. Spitzer, P. O. Simon Jr, H. Kashiwagi, J. Xu, C. Zeng, S. Vangveravong, D. Zhou, K. Chang, J. E.
McDunn, J. R. Hornick, P. Goedegebuure, R. S. Hotchkiss, R. H. Mach, W. G. Hawkins. “Use of
multifunctional sigma-2 receptor ligand conjugates to trigger cancer-selective cell death signaling.” Cancer
Res. 72(1), 201 (2012).
D. Zeng, N. S. Lee, Y. Liu, D. Zhou, C. S. Dence, K. L. Wooley, J. A. Katzenellenbogen, M. J. Welch. “64Cu
Core-Labeled Nanoparticles with High Specific Activity via Metal-Free Click Chemistry” ACS Nano, 6(6),
5209 (2012).
PHS 398/2590 (Rev. 06/09)
Page
2
Continuation Format Page